Catalyst Pharmaceuticals (CPRX) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Climate Coral Environment Environmental Green Materials Nature Offset Package Packaging Pandemic Raw Materials Regenerative Access Benefits Black Charitable Collective Bargaining Community Customer Data Privacy Death Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Human Capital Incident Injured Injuries Injury Privacy Product Quality Recall Recruit Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workforce Assessment Assurance Attorneys General Audit Bonus Bribery Chronic Classified Commitment Controversy Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Pledging Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Supermajority Sustainable Targets Tax Tenure Transparency Transparent Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On December 3, 2021, the Company held its 2021 Annual Meeting of Stockholders. The final voting results on the matters considered at the meeting were as follows:
1. Election of Directors:

Name	Votes For	Votes Against	Votes Abstained	Broker Non-Votes


Patrick J. McEnany	59,574,297	3,080,363	117,847	13,671,975
Philip H. Coelho	55,744,733	6,915,068	112,706	13,671,975
Charles B. O’Keeffe	57,495,445	5,166,109	110,953	13,671,975
David S. Tierney	57,290,927	5,331,612	149,968	13,671,975
Donald A. Denkhaus	58,881,012	3,779,909	111,586	13,671,975
Richard J. Daly	52,925,647	9,734,474	112,386	13,671,975
Molly Harper	60,787,856	1,805,179	179,472	13,671,975

2. Approval of an amendment to the Company’s 2018 Stock Incentive Plan increasing the number of shares authorized under the plan by 5,000,000 shares (from 10,000,000 shares to 15,000,000 shares):

Votes For		Votes Against		Votes Abstained		Broker Non-Votes

56,792,084		5,849,825		130,598		13,671,975

3. Approval, on an advisory basis, of 2020 compensation of our named executive officers

Votes For		Votes Against		Votes Abstained		Broker Non-Votes

59,092,977		3,432,904		246,626		13,671,975

2

4. Ratification of the selection of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021:


Votes For	Votes Against	Votes Abstained
75,659,772	739,493	45,217